Processa Pharmaceuticals, Inc. (PCSA) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Processor Pharmaceutical's first quarter 2022 earnings conference call and corporate update. At this time, all participants are on a listen-only mode. A brief question and answer session will follow the formal presentation. If you have any questions or comments during the presentation, you may press star 1 on your phone to enter the question queue at any time. As a reminder, this conference is being recorded. It is now my pleasure to introduce Jim Stanker, Chief Financial Officer. Thank you, sir. You may begin. Thank you and welcome to PROCESS's first quarter 2022 results and drug development update conference call. Joining me on the call today are our Chief Executive Officer, Dr. David Young, and our Chief Operating Officer, Mike Lloyd. Shortly before this call, we filed our first quarter 2022 Form 10-Q. I want to remind everyone that a PowerPoint presentation will accompany Dr. Young's prepared remarks. To view the PowerPoint slides, please go to the investor relations section on the company's website or to our earnings press release and click on the webcast link to follow along. I will start our call by reading the safe harbor statement. This statement is made pursuant to the safe harbor for forward-looking statements described in the private securities litigation reform act of 1995. All statements made on this call with the exception of historical facts may be considered forward-looking within the meaning of Section 27 of the Securities Act of 1933 and Section 21 of the Securities Act of 1934. Although we believe expectations and assumptions reflected in those forward-looking statements are reasonable, we can make no assurances that such expectations will prove to be correct. Actual results may differ materially from those expressed or im...